Aspen Pharmacare Holdings Limited (APNHF)
Aspen Pharmacare Holdings Limited operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Durban, NL, ZA. The stock last traded at $8.90, up 0.00% on the session, giving a market capitalisation of $3.95B. On trailing twelve-month figures it carries a trailing P/E of 26.34, a net margin of 7.6%. Its beta of 0.34 implies it has historically moved less than the broad market.
Operating worldwide, Aspen Pharmacare Holdings Limited, together with its subsidiaries, focuses on the development, production, and global distribution of specialized and branded pharmaceutical products. The company's business activities are structured into two main divisions: Commercial Pharmaceuticals and Manufacturing. Under its Anaesthetics portfolio, Aspen offers diverse products such as general anesthetics, muscle relaxants, and topical agents. Its Thrombosis brand is dedicated to a variety of injectable anticoagulants, with an emphasis on low molecular weight heparins, Xa inhibitors, and heparin derivatives. Additionally, Aspen provides a range of branded consumer, prescription, and over-the-counter medications through regional brands. These include Circadin (for sleep management), Foxair (for respiratory conditions), Maltofer (an iron supplement), Mybulen (a painkiller), and Zyloric (which controls uric acid production). Beyond its proprietary offerings, the company also manufactures and supplies active pharmaceutical ingredients (APIs) and finished dosage form products to external clients. Founded in 1850, Aspen Pharmacare Holdings Limited is headquartered in Durban, South Africa.
Aspen Pharmacare Holdings Limited is most often compared with the following Healthcare names: